Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Charles A. Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian D Shi, Lewis C. Strauss, C. Norman Coleman, Mansoor M. Ahmed

Research output: Contribution to journalArticle

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - May 30 2017

Fingerprint

Glioblastoma
Radiation
Pharmaceutical Preparations
Clinical Trials

Keywords

  • Cancer discovery
  • Clinical cancer research
  • Clinical trials
  • Experimental chemotherapy
  • Precision medicine
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Radiation-agent combinations for glioblastoma : challenges in drug development and future considerations. / Kunos, Charles A.; Galanis, Evanthia; Buchsbaum, Jeffrey; Shi, Qian D; Strauss, Lewis C.; Coleman, C. Norman; Ahmed, Mansoor M.

In: Journal of Neuro-Oncology, 30.05.2017, p. 1-7.

Research output: Contribution to journalArticle

Kunos, Charles A. ; Galanis, Evanthia ; Buchsbaum, Jeffrey ; Shi, Qian D ; Strauss, Lewis C. ; Coleman, C. Norman ; Ahmed, Mansoor M. / Radiation-agent combinations for glioblastoma : challenges in drug development and future considerations. In: Journal of Neuro-Oncology. 2017 ; pp. 1-7.
@article{76fde00049d848cf92f7fa6cd6c4460a,
title = "Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations",
abstract = "Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.",
keywords = "Cancer discovery, Clinical cancer research, Clinical trials, Experimental chemotherapy, Precision medicine, Radiotherapy",
author = "Kunos, {Charles A.} and Evanthia Galanis and Jeffrey Buchsbaum and Shi, {Qian D} and Strauss, {Lewis C.} and Coleman, {C. Norman} and Ahmed, {Mansoor M.}",
year = "2017",
month = "5",
day = "30",
doi = "10.1007/s11060-017-2458-0",
language = "English (US)",
pages = "1--7",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Radiation-agent combinations for glioblastoma

T2 - challenges in drug development and future considerations

AU - Kunos, Charles A.

AU - Galanis, Evanthia

AU - Buchsbaum, Jeffrey

AU - Shi, Qian D

AU - Strauss, Lewis C.

AU - Coleman, C. Norman

AU - Ahmed, Mansoor M.

PY - 2017/5/30

Y1 - 2017/5/30

N2 - Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

AB - Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

KW - Cancer discovery

KW - Clinical cancer research

KW - Clinical trials

KW - Experimental chemotherapy

KW - Precision medicine

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85019688888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019688888&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2458-0

DO - 10.1007/s11060-017-2458-0

M3 - Article

C2 - 28560665

AN - SCOPUS:85019688888

SP - 1

EP - 7

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -